3-[(2-chloropyridin-4-yl)oxy]-6-methyl-2-(1-methyl-1H-pyrazol-4-yl)pyridine | 1117683-98-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3-[(2-chloropyridin-4-yl)oxy]-6-methyl-2-(1-methyl-1H-pyrazol-4-yl)pyridine
• 英文别名: 3-(2-chloropyridin-4-yl)oxy-6-methyl-2-(1-methylpyrazol-4-yl)pyridine；3-(2-Chloropyridin-4-yl)oxy-6-methyl-2-(1-methylpyrazol-4-yl)pyridine
• CAS: 1117683-98-3
• 化学式: C₁₅H₁₃ClN₄O
• 分子量: 300.747
• InChiKey: ZDXZVUYFSVULEW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  52.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-[(2-chloropyridin-4-yl)oxy]-6-methyl-2-(1-methyl-1H-pyrazol-4-yl)pyridine 、 3,4,5-三甲氧基苯胺 在 palladium diacetate caesium carbonate 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 作用下， 以 1,4-二氧六环 为溶剂， 反应 0.5h， 以6%的产率得到4-[6-methyl-2-(1-methylpyrazol-4-yl)pyridin-3-yl]oxy-N-(3,4,5-trimethoxy-phenyl)pyridin-2-amine
  参考文献：
  名称：

  CHEMICAL COMPOUNDS-821

  摘要：

  该发明涉及化学式(I)的化合物，或其药学上可接受的盐，具有ALK5（TGFβR1）抑制活性，因此在抗癌活性方面有用，从而在治疗人体或动物体的方法中有用。该发明还涉及制造上述化学化合物的方法，含有它们的药物组合物，以及它们在制造用于在温血动物（如人）中产生抗癌效果的药物中的使用。

  公开号：

  US20090048269A1
• 作为产物：
  描述：

  3-羟基-2-碘-6-甲基吡啶 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 sodium carbonate 、 caesium carbonate 作用下， 以 1,4-二氧六环 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 生成 3-[(2-chloropyridin-4-yl)oxy]-6-methyl-2-(1-methyl-1H-pyrazol-4-yl)pyridine
  参考文献：
  名称：

  WO2020139636A5

  摘要：

  公开号：

  WO2020139636A5

文献信息

• (PYRIDIN-2-YL)AMINE DERIVATIVES AS TGF-BETA R1 (ALK5) INHIBITORS FOR THE TREATMENT OF CANCER
  申请人：Nexys Therapeutics, Inc.

  公开号：US20220054465A1

  公开（公告）日：2022-02-24

  The present invention relates to pharmaceutical compounds, compositions and methods, especially as they are related to compositions and methods for the treatment and/or prevention of a proliferation disorder associated with TGFβR1 activity, such as a cancer or fibrosis. The invention provides compounds of Formula (I) and Formula (II) as further described herein having an acidic moiety that enhances tissue specificity for targeted tissues and organs. The invention includes pharmaceutical compositions, pharmaceutical combinations, and methods of use of these compounds for treating conditions including cancer or fibrosis.
• [EN] PYRIDINYIIOXY PYRIDINES AS ALK5 INHIBITORS<br/>[FR] COMPOSÉS CHIMIQUES 1 - 821
  申请人：ASTRAZENECA AB

  公开号：WO2009022171A1

  公开（公告）日：2009-02-19

  The invention relates to chemical compounds of the formula (I) or pharmaceutically acceptable salts thereof, which possess ALK5 (TGFβRl) inhibitory activity and are accordingly useful for their anti-cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments for use in the production of an anti¬ cancer effect in a warm-blooded animal such as man.
• [EN] (PYRIDIN-2-YL)AMINE DERIVATIVES AS TGF-BETA R1 (ALK5) INHIBITORS FOR THE TREATMENT OF CANCER<br/>[FR] DÉRIVÉS DE (PYRIDIN-2-YL)AMINE UTILISÉS COMME INHIBITEURS DE TGF-BÊTA R1 (ALK5) POUR LE TRAITEMENT DU CANCER
  申请人：NEXYS THERAPEUTICS INC

  公开号：WO2020139636A1

  公开（公告）日：2020-07-02

  The present invention relates to pharmaceutical compounds, compositions and methods, especially as they are related to compositions and methods for the treatment and/or prevention of a proliferation disorder associated with ΤGFβR1 activity, such as a cancer or fibrosis. The invention provides compounds of Formula (I) and Formula (II) as further described herein having an acidic moiety that enhances tissue specificity for targeted tissues and organs. The invention includes pharmaceutical compositions, pharmaceutical combinations, and methods of use of these compounds for treating conditions including cancer or fibrosis.
• CHEMICAL COMPOUNDS-821
  申请人：Finlay Maurice Raymond

  公开号：US20090048269A1

  公开（公告）日：2009-02-19

  The invention relates to chemical compounds of the formula (I), or pharmaceutically acceptable salts thereof, which possess ALK5 (TGFβR1) inhibitory activity and are accordingly useful for their anti-cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments for use in the production of an anti-cancer effect in a warm-blooded animal such as man.

  该发明涉及化学式(I)的化合物，或其药学上可接受的盐，具有ALK5（TGFβR1）抑制活性，因此在抗癌活性方面有用，从而在治疗人体或动物体的方法中有用。该发明还涉及制造上述化学化合物的方法，含有它们的药物组合物，以及它们在制造用于在温血动物（如人）中产生抗癌效果的药物中的使用。
• WO2020139636A5
  申请人：——

  公开号：WO2020139636A5

  公开（公告）日：2022-12-16